<DOC>
	<DOCNO>NCT00746980</DOCNO>
	<brief_summary>Determine effect treatment efalizumab scalp hair re-growth younger adult affect severe variant alopecia areata , include alopecia totalis , alopecia universalis , severe ophiasis variant .</brief_summary>
	<brief_title>Efalizumab Treatment Alopecia , Phase II</brief_title>
	<detailed_description>This Phase II trial ( single-center , open-label , prospective study ) subject severe form alopecia areata , namely alopecia totalis , universalis , severe ophiasis , treat efalizumab ( Raptiva ) , humanize monoclonal anti-CD11a antibody reversibly inhibit T cell activation migration , weekly 48 week . We assess effect hair body re-growth well record serious adverse event serious infection , thrombocytopenia , development malignancy , severe arthralgia monitor safety outcome data . Subjects regular physical examination laboratory study throughout study , well telephone interview .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>ability provide write informed consent comply study assessment full duration study . clinical diagnosis alopecia totalis , alopecia universalis , severe ophiasis variant alopecia areata . 1840 year age . female childbearing potential , negative pregnancy test commitment use two form effective contraception ( birth control ) duration study necessary . nonsterile male , commitment use two form effective contraception ( birth control ) duration study necessary . know hypersensitivity efalizumab ( Raptiva ) component . know liver disease , include active hepatitis history autoimmune diseases cause alopecia alopecia areata . prior biologic therapy within 6 month prior study initiation . history malignancy within last ten year , except treat nonmelanoma skin cancer . woman currently pregnant lactating . intake systemic immunosuppressive agent , include oral corticosteroid , within 3 month prior study initiation . history positive PPD and/or tuberculosis . history HIV/AIDS prior enrollment efalizumab study condition investigator believe would pose significant hazard subject investigational therapy initiate . participation another simultaneous clinical trial involve investigational agent . positive HIV screen test obtain screen visit . positive QuantiFERONTB test obtain screen visit . positive hepatitis screen obtain screen visit . platelet count 150 x 10 ( 9 ) /L baseline visit . presence abnormal laboratory value obtain screen visit assess clinically significant principal investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>alopecia</keyword>
	<keyword>areata</keyword>
	<keyword>universalis</keyword>
	<keyword>severe</keyword>
	<keyword>ophiasis</keyword>
	<keyword>variant</keyword>
</DOC>